Australia's most trusted
source of pharma news
Thursday, 20 November 2025
Posted 27 February 2024 AM
Moderna has released its full year results for 2023, focusing on its late-stage pipeline which will replace lagging Covid sales.
The mRNA giant did note that it is increasing market share in the US Covid vaccine market, achieving a cumulative 48 per cent retail market share during the 2023 Autumn Covid season, a strong increase from its 37 per cent share in 2022.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.